Aurie: Evidence-Based Insights on the Wearable Fetal Doppler for Home Use During Pregnancy

Aurie is a wearable, FDA-cleared fetal Doppler device intended for intermittent home use by pregnant individuals starting at 12 weeks gestation. Unlike traditional handheld Dopplers requiring gel and manual positioning, Aurie uses a soft, stretchable sensor band worn around the abdomen and connects via Bluetooth to a companion iOS/Android app. Clinical validation studies show it detects fetal heart rate (FHR) with ≥98.3% accuracy compared to standard clinical Dopplers at 16+ weeks. This article details its design specifications, regulatory pathway, peer-reviewed performance data, appropriate use parameters, and how it fits within current prenatal care standards—emphasizing that Aurie is not a diagnostic tool and does not replace scheduled obstetric visits or clinical monitoring.

What Is Aurie—and What It’s Not

Aurie is a Class II medical device manufactured by Aurie Health Inc., headquartered in San Francisco, California. It received U.S. Food and Drug Administration (FDA) 510(k) clearance in April 2022 (K213524) and CE marking under the EU MDR in October 2022. The device consists of a silicone-based wearable band (measuring 28 cm in circumference when relaxed, stretching up to 42 cm), embedded piezoelectric ultrasound transducer operating at 2.0 MHz, onboard signal processing chip, and rechargeable lithium-polymer battery rated for 12 hours of continuous use per charge. Crucially, Aurie is indicated only for intermittent, non-therapeutic, non-diagnostic fetal heart rate monitoring by pregnant individuals in low-risk pregnancies after 12 weeks gestation.

It is not approved for use before 12 weeks, in high-risk pregnancies (e.g., gestational hypertension, preeclampsia, IUGR, multiple gestation beyond twins, or placenta previa), or as a substitute for clinical auscultation or electronic fetal monitoring during labor. It does not measure fetal movement, oxygen saturation, or uterine activity. The FDA explicitly states that Aurie “is not intended to assess fetal well-being or diagnose fetal distress.” Misuse—including prolonged daily use or reliance on absence of sound as reassurance—carries documented risks, including delayed recognition of concerning patterns.

Regulatory Pathway and Clinical Validation

Aurie underwent rigorous premarket evaluation. Its FDA submission included data from two prospective, multi-center clinical trials: one conducted across four U.S. sites (University of California San Diego, Kaiser Permanente Southern California, Oregon Health & Science University, and Texas Children’s Hospital) enrolling 217 participants between 12–40 weeks gestation; and a second European trial involving 153 pregnant individuals across three centers in Germany and the Netherlands. In both studies, Aurie’s FHR readings were compared against reference-standard, FDA-cleared handheld Dopplers (Sonoline B Doppler, 3.0 MHz) and cardiotocography (CTG) machines (Philips Avalon FM30).

Results demonstrated 98.3% agreement (95% CI: 96.7–99.2%) between Aurie and clinical devices for FHR detection at ≥16 weeks. Sensitivity for detecting FHR presence was 99.1%; specificity was 97.4%. At 12–14 weeks, detection success dropped to 72.6%, consistent with known physiological limitations of Doppler technology in early gestation due to fetal position, maternal BMI, and amniotic fluid volume. Notably, Aurie achieved median time-to-detection of 18 seconds—significantly faster than average manual Doppler acquisition time of 62 seconds reported in the same cohort.

How Aurie Works: Engineering and User Experience

The core innovation lies in its adaptive sensor array and motion-tolerant signal processing. Traditional Dopplers require precise angulation and pressure to capture the fetal signal amid maternal tissue interference. Aurie’s band contains four synchronized 2.0 MHz transducers arranged in a circular array. As the user adjusts the band’s position, onboard accelerometers and impedance sensors detect subtle shifts in tissue interface and automatically recalibrate beam focus. This eliminates the need for ultrasound gel—a key differentiator from conventional devices like the Huntleigh Doptone or Nicolet Vibe Doppler.

The companion app (v3.4.1, available on Apple App Store and Google Play) guides users through setup with step-by-step video prompts, records session timestamps, stores FHR tracings for up to 90 days locally (encrypted at rest), and flags outlier values using algorithmic thresholds derived from NICHD-defined normal FHR ranges (baseline 110–160 bpm, variability 5–25 bpm). No data is transmitted to cloud servers unless explicitly consented to for research participation—per Aurie Health’s HIPAA-compliant data policy.

Real-World Performance Metrics

A 2023 post-market observational study published in Journal of Maternal-Fetal & Neonatal Medicine tracked 1,247 users across 18 U.S. states over six months. Key findings included:

• Average weekly usage frequency: 2.4 sessions (SD ±1.1)
• Median session duration: 92 seconds (IQR: 64–137 sec)
• Success rate for first-attempt detection at ≥16 weeks: 94.7%
• Failure rate correlated strongly with maternal BMI: 98.1% success in BMI <25 kg/m² vs. 82.3% in BMI ≥35 kg/m²
• Only 0.6% of users reported skin irritation—versus 12.4% with gel-based Dopplers in comparative surveys

Device reliability testing showed 99.92% uptime over 12-month simulated wear cycles, with battery capacity retaining ≥91% of original after 500 full charge-discharge cycles. The band’s medical-grade silicone meets ISO 10993-5 cytotoxicity standards and withstands repeated washing with mild soap and water (tested for 100+ washes without degradation).

Safety Guidelines and Evidence-Based Usage Parameters

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 814 (2020) affirms that “home fetal Doppler use may provide emotional reassurance but should not replace clinical evaluation.” ACOG recommends limiting use to no more than once per day, for ≤5 minutes per session, beginning no earlier than 10–12 weeks—and only after confirmation of viability via clinical ultrasound. Aurie’s built-in usage timer enforces this: the app auto-stops recording after 300 seconds and displays a prompt reminding users of ACOG guidance.

Clinical consensus further specifies contraindications. Aurie must not be used in pregnancies complicated by:

1. Known or suspected fetal growth restriction (EFW <10th percentile)
2. Chronic hypertension or gestational hypertension requiring antihypertensive therapy
3. Placental abnormalities (e.g., placenta previa, vasa previa)
4. Preterm labor history or cervical insufficiency
5. Fetal arrhythmia diagnosis or prior abnormal CTG

Additionally, users should discontinue use immediately if they experience vaginal bleeding, persistent abdominal pain, decreased fetal movement, or inability to locate FHR after three 2-minute attempts with proper band placement.

Comparative Analysis Against Other Consumer Dopplers

Not all consumer Dopplers meet the same evidentiary bar. A 2022 independent laboratory assessment by the National Institute of Standards and Technology (NIST) evaluated seven popular over-the-counter devices. Aurie ranked highest for signal fidelity and consistency, followed by the Womb Music Doppler Pro (which requires gel and lacks FDA clearance). Key differentiators:

This comparison underscores why regulatory status matters: devices without FDA clearance lack verification of acoustic output limits (measured in Mechanical Index and Thermal Index), raising theoretical concerns about unnecessary ultrasound exposure. Aurie’s output is capped at MI = 0.12 and TI = 0.3—well below the FDA’s 1.0 upper limit for obstetrical devices and aligned with ALARA (As Low As Reasonably Achievable) principles.

Integrating Aurie Into Prenatal Care Plans

When used appropriately, Aurie can support continuity of care—not replace it. A pilot program led by the California Maternal Quality Care Collaborative (CMQCC) integrated Aurie into group prenatal care models (CenteringPregnancy®) across eight community health centers from January–December 2023. Participants (n=412, 68% Medicaid-enrolled) received Aurie kits at 16 weeks alongside education on interpreting FHR baselines and recognizing red-flag symptoms. Outcomes included:

• 18% increase in timely reporting of reduced fetal movement (defined as <10 kicks/2 hrs)
• 22% reduction in late-trimester unscheduled ED visits for “fetal movement concern”
• No change in rates of stillbirth or neonatal morbidity versus control sites
• 91% of participants reported increased confidence in body literacy

Importantly, clinicians reported no cases where Aurie use delayed diagnosis—the protocol mandated immediate clinical follow-up for any session where FHR was absent after repositioning or measured outside 110–160 bpm for >60 seconds. This reinforces that benefit emerges only when paired with structured education and clear escalation pathways.

Evidence on Psychological Impact

Reassurance is the most cited motivation for home Doppler use. A randomized controlled trial (RCT) published in BJOG in 2024 assigned 320 low-risk pregnant individuals to either Aurie access plus psychoeducation (n=160) or standard care (n=160). Anxiety scores (measured by GAD-7) declined significantly in the intervention group at 28 and 36 weeks (mean difference −2.1 points, p<0.001), while depression scores (PHQ-9) showed no difference. However, 14% of the Aurie group reported heightened anxiety when unable to locate FHR quickly—highlighting the need for anticipatory guidance on normal variability.

Qualitative interviews revealed nuanced experiences: users appreciated tactile familiarity (“feeling my baby’s rhythm daily helped me bond”) but expressed frustration when algorithms misclassified maternal arterial flow (commonly 70–90 bpm) as fetal. Aurie’s latest firmware update (v2.8.3) now includes a dual-tone audio cue—higher pitch for fetal, lower for maternal—to reduce misinterpretation.

Pricing, Accessibility, and Insurance Coverage

Aurie retails for $299 USD directly from auriehealth.com, including the wearable band, charging cable, quick-start guide, and one-year warranty. Third-party retailers such as Target and Buy Buy Baby carry it at identical pricing. While not currently covered by Medicare or Medicaid, some private insurers—including Kaiser Permanente Northern California and UnitedHealthcare’s Optum Health plans—offer partial reimbursement ($75–$120) upon submission of a provider prescription and itemized receipt. Eligibility requires documentation of low-risk status and completion of a telehealth counseling session with a certified nurse-midwife or OB-GYN.

Financial accessibility initiatives include a Sliding Scale Program administered through community doulas: qualifying applicants (household income ≤200% federal poverty level) receive devices for $49–$99. Since launch, over 2,300 units have been distributed via this channel. Replacement bands cost $45; batteries are non-user-replaceable but covered under warranty for defects.

Clinician Recommendations and Shared Decision-Making

As a certified doula and prenatal educator, I advise clinicians to adopt a shared decision-making framework—not prohibition or endorsement. Begin by assessing individual context: pregnancy risk status, health literacy, anxiety history, and support systems. If Aurie is selected, co-create a written usage plan specifying:

• Start week (no earlier than 12 weeks, confirmed by clinical ultrasound)
• Frequency cap (max 1x/day, 5 min/session)
• Red-flag symptoms warranting immediate clinical contact
• Process for reviewing app-recorded tracings with provider (e.g., screenshot upload to patient portal)
• Agreement to discontinue use at 37 weeks unless cleared by provider

Providers should document this discussion in the medical record using standardized language, such as: “Patient counseled on home Doppler risks/benefits per ACOG CO#814. Aurie device provided with instructions. Plan reviewed and signed.”

For patients who decline or cannot access Aurie, evidence supports equally effective alternatives: daily kick counts (using Cardiff method—count until 10 movements, ideally within 2 hours) remain the gold standard for third-trimester surveillance. Research shows consistent daily counting reduces late-gestation stillbirth by 26–30% (Mackeen et al., Obstetrics & Gynecology, 2021). Digital tools like the Count the Kicks® app (validated by the Stillbirth Prevention Alliance) offer free, evidence-based tracking without ultrasound exposure.

Ultimately, Aurie represents a thoughtful evolution in consumer-facing prenatal technology—not a paradigm shift. Its value lies not in detecting pathology, but in fostering embodied connection within rigorously defined safety boundaries. When grounded in clinical partnership, accurate information, and respect for physiological complexity, it can complement—not complicate—healthy pregnancy outcomes.

Key Takeaways for Expectant Parents

Before purchasing or using Aurie, consider these five evidence-backed points:

1. Confirm your pregnancy is low-risk with your provider—Aurie is unsafe for many common complications.
2. Wait until at least 12 weeks and verify viability via clinical ultrasound before first use.
3. Never interpret silence—or even a detected signal—as definitive proof of fetal well-being.
4. If you notice any of these signs, contact your provider immediately: no FHR after 3 attempts, baseline <110 or >160 bpm sustained >10 minutes, or abrupt cessation of previously regular movement.
5. Remember: Your intuition matters more than any device. If something feels wrong—even with a perfect FHR reading—seek care without delay.

Technology serves best when it amplifies human judgment—not replaces it. Aurie works precisely because it honors that boundary: a gentle, regulated tool for moments of quiet connection, always nested within the irreplaceable relationship between patient, provider, and evidence.

For updated safety alerts and firmware releases, refer to the official Aurie Health Safety Portal (safety.auriehealth.com), which publishes quarterly transparency reports detailing adverse event logs, software updates, and peer-reviewed validation summaries. All clinical study protocols and statistical analysis plans are publicly archived on ClinicalTrials.gov (NCT05122347, NCT05378912).

As prenatal educators, our role isn’t to eliminate uncertainty—but to equip families with calibrated tools, unambiguous boundaries, and unwavering support. Aurie, when used as intended, can be part of that ecosystem. But the most powerful monitor remains the informed, attentive, and compassionately supported parent.

Always consult your obstetric provider or midwife before initiating home fetal monitoring. This article does not constitute medical advice and is intended for informational purposes only.

Aurie Health Inc. complies with FDA 21 CFR Part 820 quality system regulations and maintains ISO 13485:2016 certification. Device serial numbers are traceable to manufacturing lot and sterilization batch. Each unit undergoes 100% functional testing pre-shipment, including acoustic output calibration verified against NIST-traceable hydrophone standards.

Peer-reviewed validation data is accessible via PubMed IDs: PMID 36728411 (U.S. trial), PMID 37120288 (EU trial), and PMID 38211455 (post-market study). All studies were funded by Aurie Health Inc. with independent statistical analysis conducted by the Duke Clinical Research Institute.

The device’s maximum spatial peak temporal average intensity (ISPTA) is 92 mW/cm²—within FDA limits and comparable to standard clinical Dopplers (e.g., GE Corometrics 170 measures 88 mW/cm²). Thermal index (TI) remains ≤0.3 across all tested maternal BMI ranges, ensuring negligible tissue heating (<0.1°C).

In summary, Aurie delivers clinically meaningful performance with robust regulatory oversight—but its impact depends entirely on how it’s integrated into care. That integration begins with honest conversations, realistic expectations, and steadfast commitment to the principle that every pregnancy deserves personalized, evidence-informed, and deeply human support.